MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461104 | Name: Mopidamol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mopidamol is a derivative of dipyridamole, is a phosphodiesterase inhibitor that has been shown previously to limit progression of malignancy in certain experimental animal models and in a pilot study in humans.

Chemical Structure

Mopidamol
Mopidamol
CAS#13665-88-8

Theoretical Analysis

MedKoo Cat#: 461104

Name: Mopidamol

CAS#: 13665-88-8

Chemical Formula: C19H31N7O4

Exact Mass: 421.2438

Molecular Weight: 421.50

Elemental Analysis: C, 54.14; H, 7.41; N, 23.26; O, 15.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Mopidamol; Rapenton; RA 233; RA-233; RA233;
IUPAC/Chemical Name
2,2',2'',2'''-((4-(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetrakis(ethan-1-ol)
InChi Key
FOYWNSCCNCUEPU-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H31N7O4/c27-10-6-25(7-11-28)18-20-14-15-16(22-18)17(24-4-2-1-3-5-24)23-19(21-15)26(8-12-29)9-13-30/h14,27-30H,1-13H2
SMILES Code
OCCN(CCO)c1nc2cnc(N(CCO)CCO)nc2c(N3CCCCC3)n1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 421.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Blaha H, Dierkesmann R, Feuerer W, Gatzemaier U, Geser C, Lemme J, Mall W, Ritscher R, Schneider B, Vallee D. [Adjuvant therapy of non-small cell bronchial cancer with mopidamol]. Pneumologie. 1989 Jun;43(6):299-304. German. PubMed PMID: 2547216. 2: Zacharski LR, Moritz TE, Baczek LA, Rickles FR, Edwards RL, Forman WB, Forcier RJ, Cornell CJ, Haakenson CM, Ballard HS, et al. Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188. J Natl Cancer Inst. 1988 Mar 16;80(2):90-7. PubMed PMID: 2830407. 3: Mopidamol. J Natl Cancer Inst. 1988 Jun 1;80(7):532-4. PubMed PMID: 2835491. 4: Livingston RB. Mopidamol in non-small cell lung cancer: anti-oncogene or accident? J Natl Cancer Inst. 1988 Mar 16;80(2):77-8. PubMed PMID: 2830406. 5: Trentesaux C, Jeannesson P, Carpentier Y, Kouamouo J, Jardillier JC. Effects of a new antitumor compound, mopidamol, on thymidine and 2-deoxyglucose transport in leukaemic L 1210 cells. Arzneimittelforschung. 1984;34(1):5-8. PubMed PMID: 6538421. 6: De La Cruz JP, Ortega G, Sánchez de la Cuesta F. Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity. Biochem Pharmacol. 1994 Jan 20;47(2):209-15. PubMed PMID: 8304965. 7: De La Cruz JP, Moreno A, Mérida F, García Campos J, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus. Thromb Res. 1996 Feb 1;81(3):327-37. PubMed PMID: 8928090. 8: De La Cruz JP, Villalobos MA, Palacios R, Smith-Agreda JM, Sánchez de la Cuesta F. In vitro effect of mopidamol on platelet-subendothelium interaction. Thromb Res. 1995 Jan 1;77(1):97-103. PubMed PMID: 7701482. 9: de la Cruz JP, Moreno A, Mérida F, García-Campos J, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats. Pharmacol Toxicol. 1994 Nov;75(5):250-4. PubMed PMID: 7870694. 10: De la Cruz JP, Olveira C, Gonzalez-Correa JA, Benítez A, Sánchez de la Cuesta F. Inhibition of ferrous-induced lipid peroxidation by dipyridamole, RA-642 and mopidamol in human lung tissue. Gen Pharmacol. 1996 Jul;27(5):855-9. PubMed PMID: 8842690. 11: Gastpar H. [Modification of metastasis formation by inhibition of platelet aggregation. Experimental and clinical results]. Laryngol Rhinol Otol (Stuttg). 1983 Dec;62(12):578-85. Review. German. PubMed PMID: 6369051. 12: Li XT, Hellmann K. Antitumor effect of RA233 alone and combined with radiotherapy. Clin Exp Metastasis. 1983 Apr-Jun;1(2):181-90. PubMed PMID: 6546197. 13: Stackpole CW, Fornabaio DM, Alterman AL. Failure of orally administered RA233 to influence B16 melanoma growth or metastasis. Clin Exp Metastasis. 1987 Apr-Jun;5(2):165-80. PubMed PMID: 3594974. 14: Bamford CH, Middleton IP, Al-Lamee KG. Polymeric inhibitors of platelet aggregation. II. Copolymers of dipyridamole and related drugs with N-vinylpyrrolidone. Biochim Biophys Acta. 1987 Apr 16;924(1):38-44. PubMed PMID: 3828396. 15: Gastpar H. Platelet aggregation inhibitors and cancer metastasis. Ann Chir Gynaecol. 1982;71(3):142-50. Review. PubMed PMID: 6287902. 16: Lichtner RB, Hutchinson G, Wedderburn N, Hellmann K. Antiplatelet pyrimido-pyrimidines and metastasis. Cancer Treat Rev. 1985 Dec;12(4):221-34. Review. PubMed PMID: 3009013. 17: Ambrus JL, Bannerman RM, Sills RH, Meky N, Sharma S, Stadler S, Gastpar H, Marton J, Melewski DJ. Studies on the vasoocclusive crisis of sickle cell disease. III. In vitro and in vivo effect of the pyrimido-pyrimidine derivative, RA-233: studies on its mechanism of action. J Med. 1987;18(3-4):165-98. PubMed PMID: 3480932. 18: Meky N. Effect of RA-233 on erythrocytes from patients with eczema. J Med. 1988;19(1):33-45. PubMed PMID: 3221142. 19: Bellido I, de la Cruz JP, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivative RA-642: a potent inhibitor of ferrous-induced lipid peroxidation in cell membranes. Methods Find Exp Clin Pharmacol. 1991 Jul-Aug;13(6):371-5. PubMed PMID: 1881198. 20: Bonta IL, Parnham MJ, Adolfs MJ. Mimickry of anti-granuloma effect of prostaglandin E by dibutyryl cyclic-AMP and some phosphodiesterase inhibitors. Agents Actions Suppl. 1979;(4):278-85. PubMed PMID: 91315.

View History

Glycodiazine

Glycodiazine

Sch 30497

Sch 30497

BPP

BPP

LCC03

LCC03

Sulcardine sulfate trihydrate

Sulcardine sulfate trihydrate

Morazone hydrochloride

Morazone hydrochloride